New pill aims to ease burning nerve pain in diabetes
NCT ID NCT07159243
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 2 trial tests an experimental oral drug called HL-1186 for diabetic peripheral neuropathic pain—a common, painful nerve condition caused by diabetes. About 180 adults with type 1 or type 2 diabetes will receive either HL-1186 or a placebo for 12 weeks. The main goal is to see if the drug reduces daily pain scores more than placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HL-1186 tablet
- What this could lead to
- If it works, this could lead to a new oral medication to reduce nerve pain in people with diabetes.
- What could go wrong
- This is an early Phase 2 trial with only 180 participants, so results may not apply to everyone. The drug may not prove better than a placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC PERIPHERAL NEUROPATHIC PAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A ZAP BEHIND THE KNEE MAY QUIET DIABETIC NERVE PAIN
- Can cannabis ease diabetic nerve pain? new trial seeks answers
- New pain drug mirogabalin tested in Real-World diabetes study
- New pill HRS-2129 aims to ease diabetic nerve pain
- New hope for diabetic nerve pain: experimental drug enters phase 2 trial
- Experimental nerve pain drug trial halted midway